MedTrace Logo

Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis

NCT02049203 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-07-07

No results posted yet for this study

Summary

This study will determine whether Ataciguat (HMR1766) is well-tolerated in patients with mild to moderate calcific aortic valve stenosis. The primary focus of these studies will be on changes in blood pressure and orthostatic tolerance (i.e., ability to stand up without passing out), and determining whether treatment with Ataciguat results in significant reductions in blood pressure in this patient population.

Conditions

  • Aortic Valve Stenosis

Interventions

DRUG

Ataciguat

DRUG

Placebo

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Jordan D. Miller, Ph.D.

    lead OTHER

Principal Investigators

  • Jordan Miller, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02049203 on ClinicalTrials.gov